Kvartalsrapport Q1 2023

===== SIDA 1 =====

Significant events Financial overview
1
JANUARY-MARCH
• Net sales 
amounted to SEK 1.1 M (-) 
• Operating profit 
amounted to SEK -72.7 M (-98.9) 
• Net profit 
amounted to SEK -71.0 M (-98.6) 
• Profit per share, before and after dilution, 
amounted to SEK -0.79 (-1.31)
• Cash balances at the end of the period
amounted to SEK 253.9 M (194.3) 
Selected Key Indicators
(SEK thousand)
2023
Jan-Mar
2022
Jan-Mar
2022
Jan-Dec
2021
Jan-Dec
Net sales 1 124 - 8 355 118 295 
Operating profit -72 740 -98 865 -349 350 -1 420 917
Profitafter tax -71 025 -98 587 -337 951 -1 430 317
Earnings per share before and after dilution (SEK) -0,79 -1,31 -4,11 -19,00
Cash flow from operating activities -88 997 -166 033 -420 509 -1 516 391
Cash at the end of the period 253 904 194 315 344 515 362 187
R&D costs/operating expenses, % 41% 67% 61% 46%
INTERIM REPORT 
–
 Q1 2023
Providing
 clinical
 benefit 
to patients
This publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish
version and this publication, the Swedish language version shall prevail.
JANUARY-MARCH
• Monica Shaw is appointed CEO and takes office on the 
4th of January, and Jakob Lindberg assumes role as Chief 
Scientific Officer.
• Holger Lembrér is appointed CFO and takes office on the 
18th of January 2023.
• Oncopeptides receives a research grant of SEK 3 M from 
Sweden´s Innovation Agency Vinnova, as per 28th of 
March, to explore the PDC platform in solid tumors
EVENTS AFTER THE PERIOD
• Oncopeptides issues warrants to utilize the first loan 
tranche from EIB.
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 2 =====

CEO-statement
2
Pepaxti providing clinical benefit to patients with Multiple Myeloma
The first quarter marked an important transition for Oncopeptides, establishing ourselves as a commercial organization. 
Our key priority this year is building the Pepaxti launch in Germany and initiating pricing and reimbursement discussions 
across Europe.
We have successfully hired team 
members in Germany with a broad set 
of skills, existing network, and expe-
rienceto launch drugs within haema-
tologyand multiple myeloma. This has 
allowed us to increase the coverage of 
target physicians and raise the aware-
ness and willingness to prescribe 
Pepaxti. We are leveraging our expe-
riencein Germany to consolidate our 
positioning of Pepaxtiand finalize a 
launch sequence for the rest of Europe, 
and have interesting opportunities in 
our pre-clinical pipeline, advancing the 
PDC and SPiKE platforms towards the 
clinic. After the quarter we have exten-
ded the cash runway and refocused our 
spending and decided to utilize the first 
tranche of our loan facility with the 
European Investment Bank (EIB).
A key reason I joined Oncopeptides was 
the opportunity to launch Pepaxti, as I 
believe this is an important product for 
patients with multiple myeloma. Spea-
king with physicians in Germany and 
across Europe, I have received consis-
tent feedback that more options are 
needed for patients who prioritize 
efficacy while maintaining their quality 
of life with a manageable treatment 
alternative. To address this unmet need, 
we aspire for Pepaxtito become the 
preferred treatment option in elderly 
patients with relapsed, refractory 
multiple myeloma. 
Where physicians have begun to use 
Pepaxti, we have started to see a 
progression towards depth of 
prescribing and advocacy, with new 
physicians becoming speakers for us at 
peer-to-peer events. We have 
completed a first market access 
assessment for Europe, developed a 
market access strategy, and initiated 
pricing and reimbursement discussions 
in key markets. This enables us to do a 
targeted geographic expansion in 
Europe and provides the basis for go/no 
go commercial decisions in other geo-
graphies, as well as a launch sequence 
that protects our price and maximizes 
profitability. For key markets we will 
develop our own commercial model and 
for other European markets we will 
identify profitable partnerships. We have 
already initiated a partnership with Ariti
in Greece where we have experienced 
significant interest from physicians who 
had been involved in our clinical studies. 
The market authorizations in the EU 
and UK during the second half of 2022 
have made it possible for us to extend 
patent protection for five years via 
Supplementary Protection Certificates 
(SPCs). 
I am pleased to share that our sub-
mission to the European Medicines 
Agency regarding a type II variation to 
expand the market for Pepaxtiand en-
able prescription in adult patients with 
multiple myeloma who have received at 
least two prior lines of therapies, is pro-
gressingwell. We are now planning for a 
formal marketing authorization in Q3 
2023. 
With regards to our pipeline, we have 
received a Eurostarsresearch grant of 
SEK 3 M from Sweden ́s Innovation 
Agency Vinnova, to explore the 
development of new treatment options 
for glioblastoma, an aggressive and 
incurable form of brain cancer with an 
imminent need for more effective 
therapies. The grant allows exploratory 
research to better understand the 
potential of the PDC platform in solid 
tumours such as glio-blastoma. While 
Pepaxtiand the PDC platform  has been 
validated in multiple myeloma, 
preclinical data have also demonstrated 
a potential to expand the PDC platform 
into other haematological tumours such 
as lymphoma and acute myeloid 
leukemia(AML) and solid tumours such 
as mesothelioma, triple negative breast 
cancer, retinoblastoma and liver cancer. 
We will be exploring our strategic 
options in these spaces. We will also 
continue to advance our preclinical 
proof of concept for a novel synthetic 
small polypeptide based on our Small 
Polypeptide based innate Killer Engager 
platform (SPiKE). The compound is a 
Natural Killer (NK) cell engaging 
immunotherapy that uses the affibody 
technology. The compounds enable 
superior tissue penetration and immune 
cell activation, resulting in effective 
target cell killing and potentially less 
risk of immune system exhaustion. NK-
cells are becoming increasingly 
important targets to avoid cytokine 
release syndrome (CRS), associated with 
T-cell activating immunotherapies such 
as checkpoint inhibitors, CAR-Ts and 
bispecific T-cell engagers (BiTEs). The 
small molecules enable synthetic 
production, which means that com-
pounds can be produced on a larger 
scale through a much more efficient 
and less costly process. We have 
previously received a research grant to 
explore the SPiKE platform in multiple 
myeloma in collaboration with a world 
leading research consortium. The 
project is partly financed by Vinnovaand
qualified as a Eurostarsprogram. We 
are exploring further indications given 
the flexibility of our platform to target 
any potential malignancy.
Oncopeptides has decided to utililzethe 
first of three potential tranches of our 
loan facility with the EIB, amounting to 
EUR 10 million.This increases our flexi-
bilityduring the commercialization of 
Pepaxtiand enables us to further ex-
pand our business and create value for 
patients and shareholders. As well as 
continuous cost optimization, this is 
supporting our stable cash and equity 
position. With our projected sales 
trajectory and spending base we aim to 
be a profitable company within about 3 
years.
This is the start of an exciting journey 
for Oncopeptides with a team of proud  
and highly passionate individuals who 
are excited to bring a valuable new 
treatment option in Pepaxtito patients 
with multiple myeloma. I would like to 
extend my gratitude to all shareholders, 
healthcare professionals, partners, and 
co-workers, who are making this 
possible. Together we are bringing hope 
through science.
Stockholm, May 4, 2023 
Monica Shaw  
CEO 
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 3 =====

Financial Overview
REVENUE
Net sales for the quarter amounted to SEK 1.1 
M (-). Sales during the quarter related to 
Germany. See note 5.
Gross profit for the quarter amounted to 
SEK 1.1 M (-). 
OPERATING EXPENSES
Operating expenses, excluding cost of goods 
sold, for the quarter amounted to SEK 73.9 M 
(98.9). 
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses 
amounted to SEK 30.1 M (65.8) for the quarter. 
Only a few clinical studies were ongoing 
during the quarter and the phase 3 study 
Ocean is in its final stage.  The company has 
received repayments of SEK 22.9 M during the 
quarter related to previously closed clinical 
studies, which affected the costs in a positive 
way.
MARKETING AND SALES EXPENSES
Marketing and sales expenses amounted to 
SEK 23.5 M (10.0) for the quarter. The 
expenses during the quarter has been 
affected by the commercialization activities 
following the EU approval in August 2022. 
GENERAL AND ADMINISTRATIVE EXPENSES  
General and administrative expenses 
amounted to SEK 21.8 M (23.2) for the quarter. 
EXPENSES FOR SHARE BASED 
INCENTIVE PROGRAMS 
The costs for share based related incentive 
programs amounted to SEK 4.9 M (7.4) for the 
quarter; of which provisions and payments for 
social security related expenses amounted to 
SEK -0.2 M (0.3), and expenses relating to 
share-based remuneration amounted to SEK 
5.1 M (7.1). The expenses have no cash impact 
in the current period. See note 7.
TAX AND EARNINGS
Net profit amounted to SEK -71.0 M (-98.6) for 
the quarter, corresponding to a loss per share, 
before and after dilution,  of SEK -0.79 (-1.31) 
for the quarter.
CASH FLOW, INVESTMENTS AND  
FINANCIAL POSITION
Cash flow from operating activities amounted 
to SEK -89.0 M (-166.0) for the quarter.
Cash flow from 
• Investment activities amounted to 
SEK -0.0 M (0.0) for the quarter.
• Financing activities amounted to SEK 
-1.8 M (-4.0) for the quarter.
Cash flow for the quarter amounted to SEK 
-90.8 M (-170.0).
Cash balances at the end of the period 
amounted to SEK253.9 M (194.3). Cash 
balances include short term investments at an 
amount of SEK 75.5 M, which represents 
holdings on interest bearing accounts with a 
shorter term than three months
In the fourth quarter, a loan agreement was 
concluded with the European Investment 
Bank (EIB). The facility gives Oncopeptides 
access to an unsecured loan facility of up to 
EUR 30 M. The loan agreement is divided into 
three tranches, each with a maturity of five 
years, and made available if the company 
reaches certain milestones. If the company 
exercises the full loan facility, the EIB will be 
entitled to warrants equivalent to 2.8% of 
outstanding shares in Oncopeptides - in 
addition to interest on the loan amount.
The loan can be used to support the 
continued clinical development and the 
company's commercial ventures.
Equity amounted to SEK 228.40 M (119.1) at 
the end of the period. Equity is in its entirety 
attributable to the Parent Company´s 
shareholders
EFFECTS OF COVID-19 
Covid-19 is not deemed to have any material 
effects on the financial statements.
THE WAR IN UKRAINE
The situation in the Ukraine is not deemed to 
have any material effects on the financial 
statements.
GOING CONCERN
This interim report is issued based on the 
assumption of going concern for at least 12 
months. 
Given the EU Commission's approval in 
August, the successful directed share issue 
that closed last summer, access to the as yet
unutilized commercial EIB loan, and the 
initiated commercialization in the EU, it is the 
assessment of the Board of Directors and the 
CEO that the Group will have the necessary 
liquidity for the continued operation of the 
business for at least the next twelve months. 
Should decisive conditions not be met, for 
example by sales not developing as expected, 
the Group's continued operation might be at 
risk. This means that there are circumstances 
that may give rise to significant doubts about 
the company's ability to continue operations 
without additional financing.
The company deems other risks to be 
reflected as described in the annual report 
2022.
EMPLOYEES 
The number of FTE:s for the quarter was
59 (70). 
PARENT COMPANY 
Parent company operations are aligned with 
those of the Group, why the comments for 
the Group are also relevant  for the Parent 
Company.
ONCOPEPTIDES SHARE 
At the end of the period, the number of 
registered shares eligible for trading and votes 
in Oncopeptides amounted to 90,368,660. 
AUDIT
This report has not been reviewed by the 
company’s auditor.
3O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 4 =====

Signatures
4
The Board and the CEO confirm that 
the interim report provides a true and 
fair reflection of the Group’s and the 
Parent Company’s operations, 
position and earnings and describes 
the material risks and uncertainty 
factors faced by the Parent Company
and the companies within the Group.
Stockholm, May 4, 2023
Per Wold-Olsen
Chairman
Jenifer Jackson
Board member
Cecilia Daun-Wennborg
Board member
Per Samuelsson
Board member
Jarl Ulf Jungnelius
Board member
Brian Stuglik
Board member
Monica Shaw
CEO
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 5 =====

2023 2022 2022 2021
SEK thousand Note Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Net sales 5 1 124 - 8 355 118 295
Cost of Goods Sold -11 - -6 -53 121 
Gross profit 1 113 - 8 349 65 174 
Research and development expenses -30 067 -65 828 -217 657 -679 926
Marketing and distribution expenses -23 466 -10 048 -58 102 -698 346
Administrative expenses -21 801 -23 206 -84 093 -175 459
Other operating income/expenses 1 481 217 2 153 67 640
Total operating expenses -73 853 -98 865 -357 699 -1 486 091
EBIT; Operating profit/loss -72 740 -98 865 -349 350 -1 420 917
Net financial items 468 266 11 670 -455
EBT; Earnings before taxes -72 272 -98 599 -337 680 -1 421 372
Income tax 1 247 12 -271 -8 946
Net profit -71 025 -98 587 -337 951 -1 430 317
Other comprehensive income
Items to be reclassified as profit or loss
Translation variances 64 -294 -1 380 624
Other comprehensive income after tax 64 -294 -1 380 624
Total comprehensive income attributable to 
Parent Company’s shareholders.
-70 961 -98 881 -339 331 -1 429 693
Earnings per share before/after dilution (SEK) -0,79 -1,31 -4,11 -19,00
SEK thousand Note 2023-03-31 2022-03-31 2022-12-31 2021-12-31
ASSETS
Non-current assets 20 023 29 862 21 289 27 003 
Total non-current assets 20 023 29 862 21 289 27 003
Current assets
Inventory 1 033 - - -
Current receivables 41 922 36 890 19 519 50 186
Short term investments 75 531 - - -
Cash 176 373 194 315 344 515 362 187
Total current assets 296 859 231 205 364 034 412 373
TOTAL ASSETS 316 882 261 067 385 323 439 376
EQUITY AND LIABILITIES
Equity 228 422 119 128 294 293 210 868
Total Equity 228 422 119 128 294 293 210 868
Long-term liabilities 4 414 6 353 5 358 3 219
Total long-term liabilities 4 414 6 353 5 358 3 219
Current liabilities
Trade payables 19 536 14 279 28 219 35 702
Other current liabilities 64 510 121 307 57 453 189 587
Total current liabilities 84 046 135 586 85 672 225 289
TOTAL EQUITY AND LIABILITIES 316 882 261 067 385 323 439 376
5
Condensed consolidated statement of financial positionCondensed consolidated statement of comprehensive income
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 6 =====

2023 2022 2022 2021
SEK thousand Note Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Opening Balance 294 293 210 868 210 868 576 897
Net profit -71 025 -98 587 -337 951 -1 430 317
Other comprehensive income 64 -294 -1 380 624
Total comprehensive income -70 961 -98 881 -339 331 -1 429 693
Transactions with owners
New issue of shares - - 436 015 1 106 000 
Repurchase of shares - - -438 -
Costs related to directed share issue - - -27 667 -67 053 
Share based compensation 5 090 7 106 14 812 14 229 
Exercised warrants - 34 34 10 488 
Total transactions with owners 5 090 7 141 422 756 1 063 664
Ending balance 228 422 119 128 294 293 210 868
2023 2022 2022 2021
SEK thousand Note Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Operating activities
Operating profit/loss -72 740 -98 865 -349 350 -1 420 917
Adjustment for non-cash items 5 858 8 566 36 379 -44 325
Interest received 244 - 2 616 96
Interest paid -134 -259 -883 -948
Taxes paid - 6 -38 -12 216 
Cash-flow from operating activities 
before change in working capital
-66 772 -90 552 -311 276 -1 478 309
Change in working capital -22 225 -75 481 -109 233 -38 082
Cash-flow from operating activities -88 997 -166 033 -420 509 -1 516 391
Cash-flow from investment activities - - -2 507 -339
Cash-flow from financing activities -1 806 -3 959 392 402 1 034 030
Cash-flow for the period -90 803 -169 992 -30 614 -482 701
Cash at the beginning of the period 344 515 362 187 362 187 840 255
Change in cash -90 803 -169 992 -30 614 -482 701
Effect of exchange rate changes on cash 192 2 120 12 942 4 633
Cash at the end of the period 253 904 194 315 344 515 362 187
6
Condensed consolidated statement of changes in equity Condensed consolidated statement of cash flow
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 7 =====

2023 2022 2022 2021
SEK thousand Note Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Net sales 1 124 - 560 97 577
Cost of Goods Sold -11 - -6 -12 182 
Gross profit 1 113 - 554 85 395 
Research and development expenses -29 490 -65 930 -217 164 -676 375
Marketing and distribution expenses -26 297 -15 339 -58 919 -728 382
Administrative expenses -21 822 -20 392 -77 328 -161 814
Other operating income/expenses 2 639 -549 -67 71 362
Total operating expenses -74 970 -102 210 -353 478 -1 495 209
EBIT; Operating profit/loss -73 857 -102 210 -352 924 -1 409 814
Net financial items 599 4 729 28 825 -18 725
Earnings after net financial items -73 258 -97 481 -324 099 -1 428 539
Group contribution -1 538 - -700 -
EBT; Earnings before taxes -74 796 -97 481 -324 799 -1 428 539
Tax - - - -
Net profit -74 796 -97 481 -324 799 -1 428 539
SEK thousand Note 2023-03-31 2022-03-31 2022-12-31 2021-12-31
ASSETS
Non-current assets 11 067 11 940 11 671 12 910 
Total non-current assets 11 067 11 940 11 671 12 910 
Current assets
Inventory 1 033 - - -
Current receivables 36 501 27 043 17 497 28 753 
Short term investments 75 531 - - -
Cash 163 344 150 619 328 537 321 832 
Total current assets 276 409 177 662 346 034 350 585 
TOTAL ASSETS 287 476 189 602 357 705 363 495
EQUITY AND LIABILITIES
Restricted equity 20 688 18 609 20 688 18 575 
Non-restricted capital 212 215 95 704 281 922 186 078 
Total Equity 232 903 114 313 302 610 204 653
Long-term liabilities 2 216 143 1 815 13
Total long-term liabilities 2 216 143 1 815 13
Current liabilities
Trade payables 16 831 10 467 26 277 34 875
Other current liabilities 35 526 64 679 27 003 123 954
Total current liabilities 52 357 75 146 53 280 158 829
TOTAL EQUITY AND LIABILITIES 287 476 189 602 357 705 363 495
7
Condensed Parent Company income statement Parent Company balance sheet
Condensed Parent Company statement of comprehensive income
2023 2022 2022 2021
SEK thousand Note Jan-Mar Jan-Mar Jan-Dec Jan-Dec
EBT; Earnings before taxes -74 796 -97 481 -324 799 -1 428 539
Other comprehensive income - - - -
Net profits -74 796 -97 481 -324 799 -1 428 539
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 8 =====

Notes to the consolidated and Parent Company financial statements
NOTE 1 - GENERAL INFORMATION
The interim report covers the Swedish parent company Oncopeptides AB 
(publ), Swedish corporate identity no. 556596 -6438 and its fully owned 
subsidiaries Oncopeptides Incentive AB (and its wholly owned subsidiary 
Oncopeptides Innovation 1 AB), Oncopeptides GmbH, Germany and 
Oncopeptides Inc, USA. The parent company is a Swedish public limited 
company with its registered office in Stockholm. Numbers in 
parentheses in the report refer to the figures for the corresponding 
period the previous year. The year end report was approved for 
publication on May 4, 2023.
NOTE 2 - ACCOUNTING PRINCIPLES
The interim report for the Group has been prepared in accordance with 
IAS 34 Interim Financial Reporting. The parent company applies the 
Swedish Financial Reporting Board recommendation RFR2 Accounting 
for legal entities. Oncopeptides applies, except as described below, the 
same accounting principles as in the last Annual Report. Relevant 
accounting and valuation principles could be found on pages 50 -54 of 
the Annual Report for 2022.
No new or amended standards that became effective January 1, 2023,  
have had a significant impact on the company’s financial reporting.
Oncopeptides applies ESMA’s (European Securities and Markets  
Authority) guidelines on alternative performance measures.
NOTE 3 - RISKS AND UNCERTAINTIES
Oncopeptides is exposed to a multitude of risk in its day -to-day 
operation, primarily regulatory, operational, financial, and credit risks. 
The company continuously assesses known and foreseeable risks and 
has integrated mitigating such risks as part of its short - and long-term 
business and sustainability strategy.
The company assesses that other risks remain as described in the 2022 
annual report.
NOTE 4 - ESTIMATES AND CONSIDERATIONS
This report includes forward looking statements. Actual outcomes may 
vary from what has been stated. In addition, internal factors such as 
successful management of research projects, and intellectual property 
rights may affect future financial outcomes. Going concern as well as 
other external conditions such as, but not limited to, e.g., the economic 
climate, political changes and competing research  projects that may 
affect Oncopeptides net profit. For more information see the 
Oncopeptides Annual report 2022.
NOTE 5 - REVENUE RECOGNITION
Revenue is recognized at the transaction price for goods sold, excluding 
value added tax, discounts and returns. Revenue is recognized at the
time of delivery, when Oncopeptides has fulfilled its performance 
commitment and the control of the products are transferred to the 
customer. Customers are defined as hospitals and/or clinics
and resellers who sell the products, at an intermediate stage, to the final 
user of the products. Since the final price is related to the discount
which is valid on each local market and which is paid to the patients’ 
insurance companies, the transaction price is not known upon delivery.
This is regulated by booking a provision for the estimated discount in the 
Group, based on the framework for discounts which is valid on each
market. The provision for estimated discounts is reported under the 
headline accrued expenses.
A provision for expected returns related to the withdrawal of Pepaxto
from the US market in 2021, is reported at  the closing date. The 
remaining provision is reported in the consolidated balance sheet under
Other current liabilities and amounted to SEK 22.7 M at the end of the 
first quarter.  
NOTE 6 - RELATED PARTY TRANSACTIONS
Remuneration to senior management has been paid in accordance with 
current policies. No other transactions with related parties, outside of 
the Oncopeptides Group, occurred during the period.
NOTE 7 - SHARE BASED INCENTIVE PROGRAMS
The purpose of share -based incentive programs is to promote the  
company’s long-term interests by motivating and rewarding the 
company’s senior management, founders, and other co -workers in line  
with the interest of the shareholders. Oncopeptides has currently nine
programs that include the management team, certain board  members, 
founders and employees.
Program
• 2016; ”Employee option program 2016/2023”. 
• 2017; ”Co-worker LTIP 2017” 
• 2018; ”Co-worker LTIP 2018” 
• 2019; ”Co-worker LTIP 2019”
• 2020; ”Board LTIP 2020” 
• 2021; ”Board LTIP 2021” and ”Co -worker LTIP 2021”
• 2022; ”Co -worker LTIP 2022” and ”Board SHP 2022”
For more information on the programs see Note 26 in the Annual report 
2022 as well as Agendas and Minutes from the relevant Annual General 
Meetings on the company's website www.oncopeptides.com.  
At the end of the period, full utilization (including warrants for 
securing social security contributions), of 
• Options and share awards resolved by the AGM and awarded to named 
individuals corresponding to 5,887,891 shares, would result in a 
dilution of 6.1 percent.
• Options and share awards resolved by the AGM and awarded to named 
individuals as well as those not yet awarded to individuals*, 
corresponding to 7,761,699 shares, would result in a dilution of 7.9 
percent.
* “Options and share awards not yet awarded to individuals” refers to the  
x C-shares related to Co -worker LTIP 2022 and held by the Company.
NOTE 8 - SIGNIFICANT EVENTS AFTER THE PERIOD
• Oncopeptides issues warrants to utilize the first loan tranche from EIB.
8
Group Revenue 2023 2022 2022 2021
SEK thousand Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Net sales
Goods 1 124 - 8 355 118 295 
Total net revenue 1 124 - 8 355 118 295 
Geographic market
USA - - 7 795 118 295 
Germany 1 124 - 560
Parent Company Revenue 2023 2022 2022 2021
SEK thousand Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Net sales
Goods 1 124 - 560 97 577 
Total net revenue 1 124 - 560 97 577 
Geographic market
USA - - - 97 577
Germany 1 124 - 560
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3

===== SIDA 9 =====

9
Telephone conference
Contact
Key performance measures
In  this report, certain key  
performance measures are 
presented, including measures 
that are not defined under IFRS,  
• Research and development /  
operating expenses, %, 
• Gross margin, TSEK, %.  
The company believes  that these  
measurements provides valuable 
additional information when 
evaluating the  company’s  
economic  trends. These financial  
performance  measures should 
not be viewed in isolation, nor be  
considered in replacement of 
performance indicators  that are  
prepared in accordance with  
IFRS.  
Further, such performance  
measures,  as the company has  
defined them, should not be  
compared with other performance  
measures with similar names 
used by other companies since 
definitions and calculation 
methods may vary between 
companies.  
Report Datum
Interim Q1 report 2023 4 May 2023
AGM 2023 25 May 2023
Interim Q2 report 2023 10 August 2023
Interim Q3 report 2023 8 November 2023
Oncopeptides AB
Visiting adress; Luntmakargatan 46, 111 37 Stockholm
Domicile: Västra Trädgårdsgatan 15, 111 53 Stockholm, Sweden
Telephone:
+46 8 615 20 40
E-mail: info@oncopeptides.com
Website: oncopeptides.com
This information is information that Oncopeptides is obliged to make public pursuant 
to the EU Market Abuse Regulation and the Securities Markets Act. The information 
was submitted for publication, through the agency of the contact persons set out 
above, at 08:00 CET on May 4, 2023.
Financial Calendar
The Interim report for the period and an 
operational  update  will  be presented 
by CEO Monica Shawand  members  of  
Oncopeptides Leadership  team,  
Thursday May 4, 2023, at 09:00 (CET).   
If you wish to participate via webcast, 
please use the link below. Through the 
webcast you can ask written questions.
https://ir.financialhearings.com/oncope
ptides-q1-2023 
If you wish to participate via telephone 
conference, please register on the link 
below. After registration you will be 
provided a phone numbers and a 
conference ID to access the conference. 
You can ask questions verbally via the 
telephone conference. 
https://conference.financialhearings.co
m/teleconference/?id=200728 
2023 2022 2022 2021
SEK Thousand Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Net sales 1 124 - 8 355 118 295
Gross profit1) 1 113 - 8 349 65 174
Gross margin2) 99% - 100% 55%
Registered common shares outstanding
beginning of period 90 368 660 75 291 841 75 291 841 67 939 715
end of period 90 368 660 75 307 217 90 368 660 75 291 841
C-shares for LTI programs3) 3 940 607 - 3 940 607 -
Registered shares; end of period including C-shares 94 309 267 75 307 217 94 309 267 75 291 841
Share capital at the end of period 10 479 8 367 10 479 8 366
Equity at the end of period 228 422 119 128 294 293 210 868
Earnings per share before/after dilution, kr4)
-0,79 -1,31 -4,11 -19,00
Operating loss -72 740 -98 865 -349 350 -1 420 917
Research and development expenses -30 067 -65 828 -217 657 -679 926
R&D costs/operating expenses, %5)
41% 67% 61% 46%
1) Defined by subtracting cost of goods sold from total sales. The key figure shows gross profitability of cost of goods sold inabsolute numbers.
2) Defined by dividing the sum of the company's gross profit by total sales. The key figure aims to clarify the relative profitability of goods sold.
3) For more information, please see the notice to the Annual General Meeting 2022.
4) Earnings per share before dilution are calculated by dividing earnings attributable to shareholders of the Parent Company by a weighted average number of outstanding shares during the period. 
There is no dilution effect driven by the employee stock option program, as earnings for the periods have been negative.
5) Defined by dividing the research and development costs with total operating expenses. The key performance measure provides anindication of the proportion of expenses that are attributable to the 
company’s core business.
Thesaurus
Contact
EMA European Medicines Agency 
CHMP The European Medicines Agency’s Committee for 
Medicinal Products for Human Use 
O N C O P E P T I D E S  I N T E R I M  R E P O R T  J A N U A R Y- M A R C H  2 0 2 3